Another explanation could lie in the fact that the administration of DPP4 inhibitors comes later in the path of glucose lowering medications, following metformin, SGLT-2, or GLP-1 receptor agonists, and hence, these patients may already represent a population of progressed metabolic disease and complications. The gene discussed is DPP4; the disease is metabolic disease.